New perspectives for targeting RAF kinase in human cancer

Cited by (409)

Items 201–300 of 409

1. Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
   Thomas S.C. Ng, Huiyu Hu, Stefan Kronister, Chanseo Lee, Ran Li, Luca Gerosa, Sylwia A. Stopka, Danielle M. Burgenske, Ishaan Khurana, Michael Scott Regan et al. · 2022 · Science Advances
2. Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
   Stephen J. Harwood, Christopher R. Smith, J. David Lawson, John M. Ketcham · 2023 · International Journal of Molecular Sciences
3. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways
   Hui Dang, Mengjun Sui, Qingyuan He, Jingyi Xie, Yan Liu, Peng Hou, Meiju Ji · 2023 · International Journal of Biological Macromolecules
4. Functional Classification of Fusion Proteins in Sarcoma
   Marco Wachtel, Didier Surdez, Thomas G. P. Grünewald, Beat W. Schäfer · 2024 · Cancers
5. Development of Highly Sensitive Biosensors of RAF Dimerization in Cells
   Kyoko Miyamoto, Masaaki Sawa · 2019 · Scientific Reports
6. Histidine phosphorylation in metalloprotein binding sites
   Cheryl L. Mathis, Amy M. Barrios · 2021 · Journal of Inorganic Biochemistry
7. The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition
   Young K. Chen, Toufike Kanouni, Lee D. Arnold, Jason M. Cox, Elisabeth M.M. Gardiner, Kathryn B. Grandinetti, Ping Jiang, Stephen W. Kaldor, Catherine Lee, Chun Li et al. · 2024 · Journal of Medicinal Chemistry
8. Multi-output prediction of dose–response curves enables drug repositioning and biomarker discovery
   Juan-José Giraldo Gutierrez, Evelyn Lau, Subhashini Dharmapalan, Melody J Parker, Yurui Chen, Mauricio A. Álvarez, Dennis Y.Q. Wang · 2024 · npj Precision Oncology
9. RAS GTPase signalling to alternative effector pathways
   Swati Singh, Matthew James Smith · 2020 · Biochemical Society Transactions
10. MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression
    Nataša Anastasov, Elisabeth Hirmer, Marbod Klenner, Jessica Ott, Natalie Falkenberg, Xuanwen Bao, Lisa Mutschelknaus, Simone Moertl, Stephanie Elisabeth Combs, Michael John Atkinson et al. · 2020 · Cancers
11. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer
    Benny Johnson, Scott Kopetz · 2020 · Targeted Oncology
12. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico
    Jakob Fleischmann, Andreas Feichtner, Louis DeFalco, Valentina Kugler, Selina Schwaighofer, Roland G. Huber, Eduard Stefan · 2021 · Biomolecules
13. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines
    Daniela Kocher, Lei Cao, Romain Guiho, Melanie Langhammer, Yun-Lu Lai, Pauline Becker, Hiba Hamdi, Dennis Friedel, Florian Selt, David Vonhören et al. · 2024 · Journal of Neuro-Oncology
14. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
    Thomas Sevrin, Hiroaki Imoto, Sarah Anne Robertson, Nora Rauch, Uscinnia Dyn'ko, Katerina Koubova, Kieran J. Wynne, Walter Kölch, Oleksii S. Rukhlenko, Boris Ν. Kholodenko · 2024 · Cell Reports
15. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma
    Xian Li, Guangdong Hou, Zheng Gang Zhu, Fei Yan, Fuli Wang, Di Wei, Yu Zheng, Jiarui Yuan, Wanxiang Zheng, Geng Zhang et al. · 2019 · Investigational New Drugs
16. A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies
    Muhammad Usman Ghani, Junbo Shi, Yi Du, Liping Zhong, Hongjuan Cui · 2024 · International Journal of Biological Macromolecules
17. A Catalytically Disabled Double Mutant of Src Tyrosine Kinase Can Be Stabilized into an Active-Like Conformation
    Yilin Meng, Lalima Gagan Ahuja, Alexandr P. Kornev, Susan Serota Taylor, Benoı̂t Roux · 2018 · Journal of Molecular Biology
18. Biochemical Characterization of Full‐Length Oncogenic BRAF V600E together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases
    Nicholas J. Cope, Borna Novak, Christine Candelora, Kenneth Wong, Maria Cavallo, Amber Y. Gunderwala, Zhiwei Liu, Yana Li, Zhihong Wang · 2019 · ChemBioChem
19. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
    Alberto Meneguzzo, Annalisa Lazzarotto, Mauro Alaibac · 2019 · In Vivo
20. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4
    Theresa Kircher, Tatu Pantsar, Andreas Oder, Jens Peter von Kries, Michael Juchum, Bent Pfaffenrot, Philip Klövekorn, Wolfgang Albrecht, Roland Selig, Stefan Laufer · 2020 · European Journal of Medicinal Chemistry
21. Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF‐mutated colorectal cancer
    Sakura Hiraide, Masanobu Takahashi, Yuya Yoshida, Hideharu Yamada, Keigo Komine, Chikashi Ishioka · 2021 · Cancer Science
22. Kinase inhibitors: An overview
    Sabeeha Ali, Manzar Alam, Md. Imtaiyaz Hassan · 2022 · Elsevier eBooks
23. mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase
    Xianjin Wu, Shenghua Li, Xing Hu, Xiaoliang Xiang, Megan Halloran, Linlin Yang, Terence Marques Williams, Peter J. Houghton, Changxian Shen, Zhengfu He · 2019 · Scientific Reports
24. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
    Francesca Consoli, Melissa Bersanelli, Gianluca Perego, Salvatore Grisanti, Barbara Merelli, Alfredo Berruti, Fausto Petrelli · 2019 · Clinical & Translational Oncology
25. Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights
    Gil Awada, Bart Neyns · 2022 · Current Opinion in Oncology
26. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
    Scarlet B. Urtecho, Leonardo Provenzano, Andrea Spagnoletti, Achille Bottiglieri, Chiara Carlotta Pircher, Giacomo Massa, Caterina Sposetti, Claudia Proto, Marta Brambilla, Mario Alberto Occhipinti et al. · 2024 · Lung Cancer
27. Polyacrylamide/Phytic Acid/Polydopamine Hydrogel as an Efficient Substrate for Electrochemical Enrichment of Circulating Cell-Free DNA from Blood Plasma
    Wei Ping Jia, Zhen Zhao, Jiaxue Gao, Yaoqi Wang, Lina Ma, Xianying Meng, Zhenxin Wang · 2020 · ACS Omega
28. Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges
    Tasuku Matsuoka, Masakazu Yashiro · 2021 · World Journal of Gastrointestinal Oncology
29. Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
    Ning Yi Jin, Yu Xia, Qinglei Gao · 2023 · International Journal of Oncology
30. Defining bone fide effectors of RAS GTPases
    Matthew James Smith · 2023 · BioEssays
31. Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics
    Santiago Ramón y Cajal, Stefan Hümmer, Vicente Peg, Xavier Matías‐Guiu, Inés M. de Torres, Josep Castellví, Elena A. Martínez-Sáez, Javier Hernández‐Losa · 2019 · Histopathology
32. Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination
    Mehdi Touat, Nadia Younan, Philipp Euskirchen, Maxime Fontanilles, Karima Mokhtari, Caroline Dehais, Patrick R. Tilleul, Amithys Rahimian, Adam Cain Resnick, Anne‐Paule Gimenez‐Roqueplo et al. · 2019 · JCO Precision Oncology
33. Ouabain Exhibited Strong Anticancer Effects in Melanoma Cells via Induction of Apoptosis, G2/M Phase Arrest, and Migration Inhibition
    Lei Wang, Wei Long Cai, Bing Han, Jue Zhang, Bing Yu, Ming Chen · 2021 · OncoTargets and Therapy
34. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
    Kumiko Umemoto, Yu Sunakawa · 2021 · Critical Reviews in Oncology/Hematology
35. BRAF mutations and concurrent alterations in patients with soft tissue sarcoma
    Hiroshi Kobayashi, Liuzhe Zhang, Koichi Okajima, Yuki Ishibashi, Toshihide Hirai, Yusuke Tsuda, Masachika Ikegami, Hidenori Kage, Aya Shinozaki‐Ushiku, Katsutoshi Oda et al. · 2023 · Genes Chromosomes and Cancer
36. Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function
    Sophie Bromberger, Yuliia Zadorozhna, Julia Maria Ressler, Silvio Holzner, Arkadiusz Nawrocki, Nina Zila, Alexander Springer, Martin R. Larsen, Klaudia Schossleitner · 2024 · Life Science Alliance
37. Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein
    Elisabetta Marini, Marco Marino, Giulia Gionfriddo, Federica Maione, Marta Pandini, Daniele Oddo, Marta Giorgis, Barbara Rolando, Federica Blua, Simone Gastaldi et al. · 2022 · Molecules
38. A patent review of BRAF inhibitors: 2013-2018
    Pengfei Wang, Han‐Yue Qiu, Hai‐Liang Zhu · 2019 · Expert Opinion on Therapeutic Patents
39. Citrus sudachi Peel Extract Suppresses Cell Proliferation and Promotes the Differentiation of Keratinocytes through Inhibition of the EGFR–ERK Signaling Pathway
    Shogo Abe, Misako Ueno, Mami Nishitani, Tetsuya Akamatsu, Takumi Sato, Marie Shimoda, Hiroki Kanaoka, Yoshitaka NII, Hiroko Yamasaki, Keizo Yuasa · 2020 · Biomolecules
40. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
    Jeffrey W. Zhao, Carlos Galvez, Kathryn Eby Beckermann, Douglas Buckner Johnson, Jeffrey Alan Sosman · 2021 · Expert Review of Precision Medicine and Drug Development
41. Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study
    Hamadeh Tarazi, Mohammed Ibrahim El-Gamal, Chang‐Hyun Oh · 2019 · Bioorganic & Medicinal Chemistry
42. Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma
    Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yuji Shimura, Yoshiaki Chinen, Kazuna Tanba, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Daichi Nishiyama, Reiko Isa, Junko Yamaguchi et al. · 2020 · Cancer Medicine
43. HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis
    Qiwei Jiang, Deyu Zhang, Juan Liu, Chaoyang Liang, Ronghui Yang, Cheng Zhang, Jun Wu, Jing Lin, Tianxing Ye, Lihua Ding et al. · 2023 · Science Advances
44. 14-3-3 interaction with phosphodiesterase 8A sustains PKA signaling and downregulates the MAPK pathway
    Soumita Mukherjee, Somesh Roy, Shruti Mukherjee, Amaravadhi Harikishore, Anirban Bhunia, Atin Kumar Mandal · 2024 · Journal of Biological Chemistry
45. Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics
    Kiavash Hushmandi, Najma Farahani, Behzad Einollahi, Shokooh Salimimoghadam, Mina Alimohammadi, Liping Liang, Le Liu, Gautam Sethi · 2025 · Journal of Advanced Research
46. Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF kinases
    Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2025 · Journal of Biological Chemistry
47. Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study
    Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar · 2021 · Current Research in Structural Biology
48. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer
    Ziying Zhu, Saisong Xiao, Haojie Hao, Qian Hou, Xiaobing Fu · 2019 · Current Topics in Medicinal Chemistry
49. Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma
    Katherine E. Miller, Benjamin Kelly, James Fitch, Nicole Ross, Matthew R. Avenarius, Elizabeth Varga, Daniel C. Koboldt, Daniel R. Boué, Vincent J. Magrini, Scott L. Coven et al. · 2018 · Molecular Case Studies
50. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization
    Alison Yu, Duc Huy Nguyen, Thomas Joseph Nguyen, Zhihong Wang · 2023 · Journal of Biological Chemistry
51. Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors
    Joseph Clayton, Aarion Romany, Evangelia Matenoglou, Evripidis Gavathiotis, Poulikos I. Poulikakos, Jana Shen · 2024 · eLife
52. BRAF inhibitors in Melanoma: Structural Insights, Therapeutic Resistance, and Biological Evaluation of Quinazoline Derivatives
    Arghya Paik, Gurubasavaraja Swamy Purawarga Matada, Abhishek Ghara, Rohit Pal, Gajjala Pavani, K. Hemalatha · 2025 · European Journal of Medicinal Chemistry
53. Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
    Gregg L. Semenza · 2025 · Pharmacological Reviews
54. Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics
    Robin Lorenz, Jian Wu, Friedrich W. Herberg, Susan Serota Taylor, Richard Alan Engh · 2021 · Biochemistry
55. Computational analysis of natural product B-Raf inhibitors
    Sumiran Chettri, Pujan Sasmal, Tenzin Adon, B. Sajeev Kumar, B. R. Prashantha Kumar, Nulgumnalli Manjunathaiah Raghavendra · 2022 · Journal of Molecular Graphics and Modelling
56. Theoretical analysis reveals a role for RAF conformational autoinhibition in paradoxical activation
    Gaurav Mendiratta, Edward C. Stites · 2023 · eLife
57. BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells
    Valentina Zanrè, Francesco Bellinato, Alessia Cardile, Carlotta Passarini, Stefano Di Bella, Marta Menegazzi · 2024 · International Journal of Molecular Sciences
58. Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation
    Shubhra Rastogi, Samantha Perino, Madhu Lal‐Nag, Yujin Wang, Samuel C. Blackman, Eleni Venetsanakos · 2025 · Cancer Research Communications
59. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer
    Yuxiao Xia, Xue Jiang, Yuan Huang, Qian Liu, Yin Huang, Bo Zhang, Zhanjun Mei, Dongkun Xu, Yuhong Shi, Wenling Tu · 2022 · Frontiers in Endocrinology
60. REVIEWING ADVANCES IN UNDERSTANDING AND TARGETING THE MAPK SIGNALING PATHWAY IN HEPATOCELLULAR CARCINOMA PROGRESSION AND THERAPEUTICS
    Hassan Mushtaq, Yusra Zarlashat, Alia Ambreen, Muhammad Mujahid, Saima Kausar3* and Danish Shafqat4 · 2024 · Agrobiological Records
61. From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis
    Aikaterini F. Giannopoulou, Athanassios D. Velentzas, Athanasios K. Anagnostopoulos, Adamantia Agalou, Nikolaos C. Papandreou, Stamatia A. Katarachia, Dimitra G. Koumoundourou, Eumorphia G. Konstantakou, Vasiliki I. Pantazopoulou, Anastasios D. Delis et al. · 2021 · Cancers
62. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
    Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David T. Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta V. Leshchenko, Daniel Verina et al. · 2022 · Journal of Hematology & Oncology
63. Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors
    Sai Charitha Mullaguri, Sravani Akula, Vigneshwar Reddy Ashireddygari, Partha Sarathi Sahoo, Prasad V.L.S. Burra, Ravalika Silveri, Vyshnavika Mupparapu, Meghana Korikani, Nageswara Rao Amanchi, Janakiraman Subramanian et al. · 2022 · Toxicology and Applied Pharmacology
64. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal
    Yurong Lu, Yuqing Zhao, Penggang Liu, Xiulong Xu · 2023 · Endocrine Related Cancer
65. Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy
    Eumorphia G. Konstantakou, Athanassios D. Velentzas, Athanasios K. Anagnostopoulos, Aikaterini F. Giannopoulou, Ema Anastasiadou, Issidora S. Papassideri, Gerassimos E. Voutsinas, George Th. Tsangaris, Dimitrios J. Stravopodis · 2017 · Journal of Proteomics
66. DoMY-Seq: A yeast two-hybrid–based technique for precision mapping of protein–protein interaction motifs
    Pau Castel, Ann E Holtz-Morris, Yong-Won Kwon, Bernhard P. Suter, Frank P. McCormick · 2020 · Journal of Biological Chemistry
67. Tracking mutation and drug-driven alterations of oncokinase conformations
    Andreas Feichtner, Valentina Kugler, Selina Schwaighofer, Thomas Nuener, Jakob Fleischmann, Eduard Stefan · 2022 · memo - Magazine of European Medical Oncology
68. Pharmacokinetic Evaluation of [ 11 C]CEP-32496 in Nude Mice Bearing BRAF V600E Mutation-Induced Melanomas
    Cuiping Jiang, Lin Xie, Yiding Zhang, Masayuki Fujinaga, Wakana Mori, Yusuke Kurihara, Tomoteru Yamasaki, Feng Wang, Ming‐Rong Zhang · 2018 · Molecular Imaging
69. Identification and Biological Evaluation of Novel Type II B‐RafV600E Inhibitors
    Pengfei Wang, Ze‐Feng Wang, Han‐Yue Qiu, Yue Huang, Huimin Hu, Zhong‐Chang Wang, Hai‐Liang Zhu · 2018 · ChemMedChem
70. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
    Winfrey Pui Yee Hoo, Pui Yan Siak, Lionel Lian Aun In · 2019 · Current Topics in Medicinal Chemistry
71. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma
    Anastasios Dimou, Gregory S. Barron, Daniel T. Merrick, Jason Kolfenbach, Robert Charles Doebele · 2020 · BMC Cancer
72. Impact of protein and small molecule interactions on kinase conformations
    Valentina Kugler, Selina Schwaighofer, Andreas Feichtner, Florian Enzler, Jakob Fleischmann, Sophie Luise Strich, Sarah Schwarz, Rebecca Wilson, Philipp Tschaikner, Jakob Troppmair et al. · 2024 · eLife
73. Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategies
    Ye Liu, Ihsan Ullah, Youyong Yuan, Jun Wang · 2026 · Advanced Drug Delivery Reviews
74. Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities
    Jakob Fleischmann, Selina Schwaighofer, Louis De Falco, Florian Enzler, Andreas Feichtner, Valentina Kugler, Philipp Tschaikner, Roland G. Huber, Eduard Stefan · 2023 · PNAS Nexus
75. A comprehensive review of targeting RAF kinase in cancer
    Md. Arafat Hossain · 2024 · European Journal of Pharmacology
76. Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis
    Benjamin L. Green, Robert Grant, Christopher T. Richie, Bishwanath Chatterjee, Michelly Sampaio De Melo, Frederic G. Barr, Karel Pacák, Sunita Kishore Agarwal, Naris Nilubol · 2022 · European Journal of Endocrinology
77. Promotion of squamous cell carcinoma tumorigenesis by oncogene‐mediated THG‐1/TSC22D4 phosphorylation
    Nohara Goto, Hiroyuki Suzuki, Ling Zheng, Yasuhito Okano, Yukari Okita, Yukihide Watanabe, Yukinari Kato, Mitsuyasu Kato · 2023 · Cancer Science
78. Quest for Clinically Effective RAF Dimer Inhibitors
    Jenny Y. Xue, Piro Lito · 2020 · Journal of Clinical Oncology
79. Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy
    Abygail G. Chapdelaine, Gongqin Sun · 2024 · ACS Pharmacology & Translational Science
80. Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib
    Piotr Kawczak, Tomasz Bączek · 2025 · Journal of Clinical Medicine
81. Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
    Martin Salzmann, Alexander Wald, Henner M. Stege, Carmen Loquai, Lisa Zimmer, Kinan Maurice Hayani, Lucie Heinzerling, Ralf Gutzmer, Alexander Enk, Jessica C. Hassel · 2023 · Cancers
82. Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity
    Sungpyo Hong, Myeongjin Jeon, Jeonghee Kwon, Hanbyeol Park, Go‐Eun Lee, Kilwon Kim, Soonkil Ahn · 2023 · Current Issues in Molecular Biology
83. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
    David K. Lau, Matthew Burge, Amitesh Chandra Roy, Ian Chau, Daniel G. Haller, Jeremy David Shapiro, Marc Peeters, Nick Pavlakis, Christos Stelios Karapetis, Niall Christopher Tebbutt et al. · 2020 · Expert Review of Anticancer Therapy
84. Age-associated changes in type I collagen promote the invasion of BRAFV600E mutated melanoma cells and their resistance to targeted therapies within three-dimensional matrix models
    Laetitia Florent, Charles Saby, Marie-Pierre Courageot, Christine Terryn, Laurence Van Gulick, Jade Vanmansart, Florian Slimano, Hamid Morjani · 2025 · Biomedicine & Pharmacotherapy
85. Per- and polyfluorinated active pharmaceutical ingredients: Overview and alternatives
    Johanna Greinke, Petra Mußler, Gerd Maack, Martin J. Hug, Michael Müller, Gunther Speichert · 2026 · Sustainable Chemistry and Pharmacy
86. A comprehensive review of RAF kinase: advances in inhibition strategies for drug development
    Dilay Kahvecioglu · 2025 · Journal of Molecular Structure
87. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF
    Jae Min Ham, Myeongbin Kim, Tae Ho Kim, Seong Eon Ryu, Hwangseo Park · 2024 · International Journal of Molecular Sciences
88. Regorafenib in patients with pretreated advanced melanoma: a single-center case series
    An-Sofie Vander Mijnsbrugge, J Cerckel, Iris Dirven, Jens Tijtgat, Manon Vounckx, Nele Claes, Bart Neyns · 2024 · Melanoma Research
89. 2,2’- Bipyridine Derivatives Exert Anticancer Effects by Inducing Apoptosis in Hepatocellular Carcinoma (HepG2) Cells
    PRIYANKA PRIYANKA, Somdutt Mujwar, Ram Bharti, Thakur Gurjeet Singh, Neeraj Khatri · 2024 · Journal of Hepatocellular Carcinoma
90. On the development of B-Raf inhibitors acting through innovative mechanisms
    Luca Pinzi · 2022 · F1000Research
91. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment
    Aoli Wang, Juan Liu, Xixiang Li, Fengming Zou, Ziping Qi, Shuang Qi, Qingwang Liu, Zuowei Wang, Jiangyan Cao, Zongru Jiang et al. · 2023 · European Journal of Pharmacology
92. Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms
    Qing-Shan Li, Bang-Nian Shen, Hua‐Jian Xu, Ban‐Feng Ruan · 2020 · Anti-Cancer Agents in Medicinal Chemistry
93. Replication Study: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Steven Pelech, Curtis Gallagher, Catherine Sutter, Lambert Yue, John Kerwin, Ajay Bhargava, Elizabeth J. Iorns, Rachel Tsui, Alexandria Denis, Nicole Perfito et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
94. Enzyme Is the Name—Adapter Is the Game
    Michael Huber, Tilman Brummer · 2024 · Cells
95. Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growth
    Marwa Mahmoud Khalaf, Marina N. Malak, Tariq Ghazi Alsahli, Musaad M Althobaiti, Mohamed A. Hamzawy, Maha M. Abdel‐Fattah · 2025 · Fundamental and Clinical Pharmacology
96. Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies
    Rohitas Deshmukh, Shekhar Verma, Phool Singh Yaduwanshi, Anubhav Dubey, Mamta Kumari · 2025 · Current Cancer Drug Targets
97. Allosteric site engagement and cooperativity mechanism by PHI1 for BRAFV600E kinase inhibition
    Xiaole Xu, Song Luo, Qihang Wang, Enhao Zhang, Jinxin Liu, Lili Duan · 2025 · International Journal of Biological Macromolecules
98. EndoBind detects endogenous protein-protein interactions in real time
    Anke Bill, Sheryll Espinola, Daniel Alexander Guthy, Jacob R. Haling, Mylene Lanter, Min Lu, Anthony Marelli, Angelica Mendiola, Loren J. Miraglia, Brandon L. Taylor et al. · 2021 · Communications Biology
99. Natural and Modified Oligonucleotide Sequences Show Distinct Strand Displacement Kinetics and These Are Affected Further by Molecular Crowders
    Ivana Domljanovic, Alessandro Ianiro, Curzio Rüegg, Michael Mayer, Maria Taskova · 2022 · Biomolecules
100. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature
     Hirra A. Chaudhary, Timothy Lewis Cannon, Arthur Winer · 2024 · Drugs in R&D